Current Report Filing (8-k)
May 08 2019 - 5:17PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
May 7, 2019
Precision Therapeutics Inc.
(Exact name of registrant as specified in charter)
Delaware
|
|
001-36790
|
|
83-4360734
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
2915 Commers Drive, Suite 900
Eagan, Minnesota 55121
(Address of principal executive offices)
(651) 389-4800
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed from last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
o
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant
to Rule 14-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240. 13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined
in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth company
o
If an emerging growth company, indicate by check mark if the registrant has elected not
to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act.
o
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, $0.01 par value
|
AIPT
|
Nasdaq Capital Market
|
|
Item 1.01.
|
Entry Into Material Definitive Agreement.
|
On May 7, 2019, the Company and Richard Gabriel
executed an amended and restated Consulting Agreement (as amended, the “Agreement”), effective as of May 1, 2019. Mr.
Gabriel is a member of the Company’s Board of Directors. The Agreement amends and restates the consulting agreement entered
into with Mr. Gabriel effective April 1, 2018. The term of the Agreement is one year, but the Company has the option to extend
the Agreement for consecutive three-month periods. Under the Agreement, Mr. Gabriel will receive compensation of $13,500 per month
in cash. Under the preceding consulting agreement dated April 1, 2018, Mr. Gabriel’s compensation was $12,000 per month,
and he received a grant of 240,000 performance-restricted stock units under the Company’s Amended and Restated 2012 Stock
Incentive Plan, with the vesting and payment of the restricted stock units based on certain performance milestones. The Agreement
includes customary confidentiality provisions.
The foregoing summary of the Agreement is qualified in all respects
by the Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by this reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 8, 2019
|
PRECISION THERAPEUTICS INC.
|
|
|
|
|
|
By:
|
/s/ Bob Myers
|
|
|
|
Bob Myers
|
|
|
|
Chief Financial Officer
|
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From Apr 2024 to May 2024
Precision Therapeutics Inc. (NASDAQ:AIPT)
Historical Stock Chart
From May 2023 to May 2024